On Jan. 30, somebody will have to climb to the top of Orlando Health’s 10-story Charles Lewis Pavilion to cover up—or start removing—the backlit letters that, with a halo effect created by LED lights, broadcast the health system’s affiliation with MD Anderson Cancer Center.
In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.
